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Aims: Myocarditis and subsequent dilated cardiomyopathy are major causes of heart failure in young
adults. Experimental autoimmune myocarditis (EAM) is a mouse model of post-infectious myocarditis
and inﬂammatory cardiomyopathy. The pathological role of endothelin (ET) in myocarditis has not
been elucidated.
Main methods: EAMwas induced by immunization of cardiac myosin peptide with complete Freund's adju-
vant on days 0 and 7 in BALB/c mice. An ETA/ETB dual receptor antagonist, SB209670, was administered by a
continuous infusion from a subcutaneous pump for 2 weeks.
Key ﬁndings: An increase in the heart-to-body weight ratio was observed in SB209670-treated mice com-
pared with vehicle-treated mice. Heart pathology in SB209670-treated mice was remarkable for gross in-
ﬂammatory inﬁltration, in contrast to the lesser inﬂammation in the hearts of vehicle-treated mice. We
found that an ET blockade decreased the number of Foxp3+ regulatory T cells in the heart. The ET blockade
also inhibited the expression of the suppressor of cytokine signaling 3 that plays a key role in the negative
regulation of both Toll-like receptor- and cytokine receptor-mediated signaling. EAM is a CD4+ T cell-
mediated disease. CD4+ T cells isolated from SB209670-treated EAMmice produced less IL-10 andmore in-
ﬂammatory cytokines, IL-6 and IL-17, than those isolated from vehicle-treated mice.
Signiﬁcance: The ET receptor antagonist exacerbated autoimmune myocarditis in mice. Our novel ﬁndings
suggest that ET may play an important role in the regulation of inﬂammation in myocarditis.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Myocarditis is an inﬂammatory disease of the myocardium and one
of the leading causes of dilated cardiomyopathy (DCM), which is cur-
rently the most frequent reason for heart transplantation (Kindermann
et al., 2012). Viral infections are thought to be themost common prima-
ry cause ofmyocarditis inWestern countries (Leuschner et al., 2009). Al-
though its pathogenesis remains unclear, there is substantial evidence
that a post-viral autoimmune-mediated response to cardiac antigens
critically contributes to the development andprogression ofmyocarditis
(Kindermann et al., 2012; Lazzerini et al., 2013). On this basis, two ani-
mal models of experimental myocarditis have been used and have
greatly advanced our knowledge of the pathogenesis of the disease;
virus-induced myocarditis and experimental autoimmune myocarditis
(EAM) (Lazzerini et al., 2013).
Endothelin (ET) has emerged as an important participant in the path-
ophysiology of a variety of cardiovascular diseases (Barton et al., 1998;culty of Medicine, University of
n. Tel./fax: +81 29 853 3143.
This is an open access article under thMurakoshi et al., 2002; Sakai et al., 1996; Stewart et al., 1991). Experi-
mental and clinical studies have demonstrated that the activation of the
ET system in many diseases is characterized by inﬂammation or ﬁbrotic
remodeling. Several ET antagonists have been discovered, which has
helped elucidate the mechanisms by which ET mediates its effects.
There are a few publications on the effects of ET receptor blockers on
virus-induced myocarditis models (Marchant et al., 2009; Ono et al.,
1999; Seta et al., 2000), and the efﬁcacy of an ET receptor blockade on
viralmyocarditis is still controversial. In amousemodel of Coxsackievirus
B3 (CVB3)-induced myocarditis, Bosentan, an ETA/ETB dual receptor
blocker, improved cardiac function, but enhanced the viral load andmyo-
carditis severity through ETA receptor mediated p38 MAPK activation
(Marchant et al., 2009). Thus, antagonism of ET signaling is potentially
a desirable therapeutic strategy for cardiac dysfunction; however it is
still unclear whether an ET blockade is useful for controlling the inﬂam-
mation itself or not.
To answer this question, we evaluated the effect of an ET receptor
blockade on EAM in mice. EAMwas induced by immunization with car-
diacmyosin peptide, which allowed us to examine the effect of ET recep-
tor blockers onmyocardial inﬂammation under infectious pathogen-free
conditions.e CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Study approval
All animal experiments were approved by the Institutional Animal
Experiment Committee of the University of Tsukuba.Mice
BALB/c mice were purchased from CLEA Japan. We used 6- to 8-
week-old male mice.Immunization protocol
The mice were immunized with 100 μg of murine cardiac α-
myosin heavy chain (MyHC-α) peptide (MyHC-α614–629 [Ac-
RSLKLMATLFSTYASADR-OH]; Toray Research Center) emulsiﬁed
1:1 in phosphate buffered saline (PBS)/complete Freund's adjuvant
(CFA) (1 mg/ml; H37Ra; Sigma-Aldrich) on days 0 and 7 as de-
scribed previously (Sonderegger et al., 2008; Tajiri et al., 2012,
2013).Treatment
The mice were given either an ETA/ETB dual receptor antagonist,
SB209670 [(+)-(1S,2R,3S)-3-(2-carboxymethoxy4-methoxyphenyl)-
1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic
acid] (n = 15) (10 mg/kg/day: SmithKline Beecham Pharmaceuticals),
or saline (n = 15) (vehicle), subcutaneously using an ALZET® mini-
osmotic pump (Model 2002, DURECT Corporation), implanted in the
back.Wepreviously investigated the effect of SB209670 on thedevelop-
ment of hypertension, cardiac hypertrophy, glomerulosclerosis, and
renal vascular wall thickening in transgenic hypertensive mice with
over-expression of both human renin and angiotensinogen genes
(Maki et al., 2004). The dose of the S209670 (10 mg/kg/day) was con-
ﬁrmed to be adequate to completely inhibit the effects of the ET-1 ad-
ministered in the mice. The mice were treated for 2 weeks from day 0
to day 14 after immunization and sacriﬁced on day 14 for further
analyses.Histopathological examination
Myocarditis severity was scored on hematoxylin and eosin (H&E)-
stained sections using grades from 0 to 4: 0, no inﬂammation; 1, less
than 25% of the heart section involved; 2, 25 to 50%; 3, 50 to 75%; and
4, more than 75% as described previously (Sonderegger et al., 2008;
Tajiri et al., 2012, 2013). Two independent researchers scored the slides
separately in a blinded manner.Flow cytometric analyses and intracellular cytokine staining
Heart inﬂammatory cells were isolated and processed as previously
described (Eriksson et al., 2003; Valaperti et al., 2008). For the ﬂow cy-
tometric analysis of the surface markers and cytoplasmic cytokines, the
cells were stained directly with conjugated ﬂuorescence antibodies and
analyzed with a FACSCalibur instrument (BD Biosciences). For the anal-
ysis of the intracellular cytokine production, the cells were stimulated
with 50 ng/ml of phorbol 12–myristate 13–acetate (PMA), 750 ng/ml
of ionomycin (Sigma-Aldrich) and 10 μg/ml of brefeldin A (eBioscience)
for 5 h. The ﬂuorochrome-conjugated, mouse-speciﬁc monoclonal anti-
bodies purchased from eBioscience, included CD4 and forkhead box P3
(Foxp3).Cytokine ELISA
For the analysis of the cytokines and chemokines in the heart, the
hearts were homogenized in media containing 2.5% fetal bovine
serum. The supernatants were collected after centrifugation and stored
at−80 °C. The concentrations of cytokines and chemokines in the heart
homogenates and culture supernatants were measured with
Quantikine ELISA kits (R&D Systems).Isolation of dendritic cells (DCs) and CD4+ T cells
We used magnetic-activated cell sorting kits for the cell isolation
(CD11c MicroBeads for DC isolation, CD4+CD62L+ T Cell Isolation Kit
II for naïve CD4+ T-cell isolation and CD4+ T Cell Isolation Kit II for
CD4+ T-cell isolation, Miltenyi Biotec).In vitro T-cell differentiation
Puriﬁed naïve CD4+CD62L+ T cells were stimulated with anti-CD3
1 μg/ml (R&D Systems) and anti-CD28 1 μg/ml (Acris Antibodies),
with or without ET-1 under T helper (Th)1-, Th2-, Th17- or Treg polar-
izing conditions for 48 h. Th1 condition: IL-12 (10 ng/ml) and anti-IL-4
antibody (10 μg/ml). Th2 condition: IL-4 (10 ng/ml), anti-IL-12
(10 μg/ml), and anti-IFN-γ (10 μg/ml). Th17 condition: transforming
growth factor (TGF)-β (10 ng/ml), IL-6 (20 ng/ml), IL-23 (20 ng/ml),
anti-IL-4 (10 μg/ml), anti-IL-12 (10 μg/ml) and anti-IFN-γ (10 μg/ml).
Treg condition: TGFβ1 (10 ng/ml), anti-IL-4 (10 μg/ml), anti-IL-12
(10 μg/ml), and anti-IFN-γ (10 μg/ml). The cytokines and antibodies
were obtained from the R&D Systems except for the TGF-β (BioLegend).Quantitative real-time reverse transcription polymerase chain
reaction (QRT-PCR)
The total RNA was prepared using TRIzol reagent (Invitrogen) ac-
cording to the manufacturer's instructions. The cDNA was synthesized
from 1 μg of the total RNA by reverse transcriptase (Takara). QRT-PCR
analysis was performed with LightCycler (Roche Diagnostics). The oli-
gonucleotides used for the PCR ampliﬁcation were the following: Ece1
forward, TGGAGGTTATGTATGGGACGA; Ece1 reverse, GGTTGTTTTCCG
TGTCACTCA; Edn1 forward, TCCTTGATGGACAAGGAGTGT; Edn1 reverse,
CCCAGTCCATACGGTACGA; Edn2 forward, AGACCTCCTCCGAAAGCTG;
Edn2 reverse, TTTCTTGTCACCTCTGGCTGTA; Edn3 forward, GCACCAGA
GATGTCACCAGTT; Edn3 reverse, AGTCTCCCGCATCTCTTCTG; Ednra for-
ward, TGTGAGCAAGAAATTCAAAAATTG; Ednra reverse, ATGAGGCTTT
TGGACTGGTG; Ednrb forward, TAGAGGCAACCGGGCTAGT; Ednrb re-
verse, GGGGAGTGAAGACAGGACAC; Ifng forward, ATCTGGAGGAACTG
GCAAAA; Ifng reverse, TTCAAGACTTCAAAGAGTCTGAGGTA; Il4 forward,
CATCGGCATTTTGAACGAG; Il4 reverse, CGAGCTCACTCTCTGTGGTG;
Il17a forward, TGTGAAGGTCAACCTCAAAGTCT; Il17a reverse, GAGGGA
TATCTATCAGGGTCTTCAT; Socs3 forward, ATTTCGCTTCGGGACTAGC;
Socs3 reverse, AACTTGCTGTGGGTGACCAT; Hprt forward, TCCTCCTCAG
ACCGCTTTT; and Hprt reverse CCTGGTTCATCATCGCTAATC. The data
were normalized by the level of the Hprt expression in each
sample.Statistical analysis
Statistical analyses were performed using the two-tailed t test or
Mann–WhitneyU test, for experiments comparing two groups. Formul-
tiple comparisons, one-way analysis of variance with Dunnett's post-
hoc test was used. P values b 0.05 were considered statistically
signiﬁcant.
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Fig. 1. The expression of ET-related genes in the EAMhearts and draining lymph nodes. EAMwas induced by a cardiac myosin peptide immunization on days 0 and 7.We obtained hearts
(n = 5mice each day) and draining lymph nodes (n = 4 mice each day) at days 0, 1, 3, 6, 9, 12, 16, 20, 25 and 29, and extracted the mRNA from them. The expression of the ET-related
genes was quantiﬁed by QRT-PCR. The results of one of two representative experiments are shown. The data were normalized by the basal gene expression (day 0). Data are expressed as
the mean ± SEM. *P b 0.05 vs. day 0.
290 K. Tajiri et al. / Life Sciences 118 (2014) 288–296
291K. Tajiri et al. / Life Sciences 118 (2014) 288–296Results
The expression of ET-related genes during the course of EAM
First, we checked the expression of ET-related genes in the EAM
hearts and the draining lymph nodes (Fig. 1). The ET-1 was elevated
in the early phase especially in the lymph nodes. On the other hand,
the ET-2 was elevated in the chronic phase. The ET-3 level did not
change signiﬁcantly throughout the disease course. The endothelin
converting enzyme-1 (ECE-1) was upregulated in the very early phase
in the lymph nodes. Interestingly, the ETA-receptor expression was
downregulated in the heart, but upregulated in the lymph nodes. The
ETB-receptor was upregulated in the heart and lymph nodes in the
early phase. Thus, the ET-related gene expression changed in the course
of the disease. However, the pathological role of the ET system in myo-
carditis has not been elucidated.1
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Fig. 2. ETA/ETB dual receptor blocker exacerbates autoimmunemyocarditis. EAMmice were trea
after immunization. (A) Representative H&E-stained sections of the hearts. Scale bars, 500 or 10
weight ratios of control and SB209670-treatedmice (n= 7 per group). The results of one of twoAn ETA/ETB dual receptor blocker exacerbates autoimmune myocarditis
Next, we sought to determine the in vivo effects of the ET receptor
blockade on EAM. As shown in Fig. 1, the ET-1 gene expression elevated
immediately after the 1st immunization in the lymph nodes, and the
peak of the inﬂammatory response in the heart occurred on day 14 in
this EAM model. Therefore we administered an ETA/ETB dual receptor
antagonist, SB209670, by a continuous infusion with a subcutaneous
pump from day 0 to day 14, and the mice were sacriﬁced on day 14.
As shown in Fig. 2A, the hearts from the SB209670-treatedmice had se-
vere inﬂammation with mononuclear cell inﬁltration with a higher
myocarditis severity score (Fig. 2B). The heart-to-body weight ratio in
the SB209670-treated mice was signiﬁcantly increased compared to
that in the control mice (Fig. 2C). We also examined whether the
SB209670 treatment had an effect on the cytokine and chemokine mi-
lieu in the heart. On day 14 after the MyHC-α immunization, the heart0
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0 μm. (B)Myocarditis severity in the heart sections (n=12 per group). (C) Heart-to-body
representative experiments are shown. Data are expressed as themean± SEM. *P b 0.05.
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Fig. 4. The SOCS3 gene expression in the EAMhearts and draining lymphnodes. The hearts
(n=5mice each day) and draining lymphnodes (n=4mice each day)were harvested at
days 0, 1, 3, 6, 9, 12, 16, 20, 25 and 29, and we extracted the mRNA from them. The SOCS3
gene expression was quantiﬁed by QRT-PCR. The results of one of two representative ex-
periments are shown. The data were normalized by the basal gene expression (day 0).
Data are expressed as the mean ± SEM. *P b 0.05 vs. day 0.
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amounts of proinﬂammatory cytokines, including IL-1β and IL-17A,
and chemokines, including chemokine (C–C motif) ligand (CCL)3 and
CCL5 and chemokine (C–X–C motif) ligand (CXCL)1 (Fig. 3). Thus, an
ET receptor blocker exacerbated the EAM development, which
corresponded to an increase in the proinﬂammatory cytokines and
chemokines in the heart.
ET receptor antagonist downregulated suppressor of cytokine signaling
(SOCS)3 gene expression
SOCS proteins are negative regulators of cytokine signaling
(Dimitriou et al., 2008; Yoshimura et al., 2007). SOCS3 is a key
negative-feedback regulator of gp130, which is a common receptor
component of the IL-6 cytokine family (Yajima et al., 2011). The major
function of SOCS3 is inhibition of signaling by the IL-6 family of cyto-
kines, causing inhibition of STAT3 activation (Yoshimura et al., 2007).
In the early phase of EAM, the SOCS3 gene expression was upregulated
in the draining lymph nodes and hearts (Fig. 4), and then downregulat-
ed, coincident with disease remission.
We then examined the effect of SB209670 treatment on the gene ex-
pression of SOCS3, and found that it was downregulated on day 14 in
the hearts (Fig. 5A). It has recently been reported that SOCS3 in the
antigen-presenting cells (APCs), e.g., DCs and macrophages, regulates
inﬂammation and protects against detrimental inﬂammatory responses
(Li et al., 2006; Qin et al., 2012). To examine the effect of the ET-1 on the
SOCS3 gene expression in DCs, we isolated the DCs from healthy mice
and stimulated them with ET-1 at various concentrations. As shown in
Fig. 5B, the SOCS3 gene expression was upregulated in a dose-
dependent manner by the ET-1 stimulation. We also found that an
ETA-receptor antagonist, BQ-123, but not an ETB-receptor antagonist,
A-192621, blocked the ET-1-altered SOCS3 gene expression (Fig. 5C).
These results suggest that ET-1–ETA-receptor signaling may increase
the SOCS3 gene expression in the DCs, which provides protection from
myocarditis through deactivation of inﬂammatory responses.
Cardiac myosine-speciﬁc CD4+ T cell response and cytokine production
EAM is a CD4+ T cell-mediated disease (Eriksson et al., 2003;
Fairweather et al., 2001). To evaluate the myosin-speciﬁc T-cell func-
tion, the CD4+ T cells were isolated from myocarditis mice and0
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294 K. Tajiri et al. / Life Sciences 118 (2014) 288–296Tregs are a subpopulation of T cellswhichmodulate the immune system
and express Foxp3, a master regulator in the development and function
of Tregs. Tregs are known to play a crucial role in preventing autoim-
mune disorders and actively controlling autoimmune responses
(Shevach et al., 2006; Zheng and Rudensky, 2007). In the SB209670-
treated hearts, the Foxp3+ Tregs were more decreased than in the
vehicle-treated hearts (Fig. 7).
ET-1 does not have a direct effect on CD4+ T-cell differentiation
Therefore, we wondered whether ET had a direct effect on the T-
cell differentiation. To answer this question, we isolated naïve CD4+
T cells from healthy mice and cultured them with ET-1 for 3 days,
and then analyzed the T-cell differentiation. ET-1 did not affect the
production of the Th1 cytokine IFN-γ, Th17 cytokine IL-17 or Th2 cy-
tokine IL-4. Further, the expression of the Foxp3, a master regulator
in the development of Tregs, was not affected by ET-1 (Fig. 8A and
B). Thus, ET-1 did not directly inﬂuence the T-cell differentiation.
We also examined the possibility of a situation in which ETA- and
ETB-receptor-mediated actions produce opposing effects and
interact with each other. ET-1 did not inﬂuence the T-cell differenti-
ation in the absence or presence of selective ETA- or ETB-receptor
antagonists (Fig. 8C). These results may have denied the possibility
of a functional antagonism of ETA-mediated and ETB-mediated
actions.
Discussion
The lymph node is a critical crossroad for encounters between APCs,
antigenic substances from lymph and lymphocytes recruited into lymph
nodes from the blood (Gretz et al., 1997). Interestingly, various ET-
related gene expressions were more dramatically changed in thelymph nodes rather than in the hearts during the course of the EAM
(Fig. 1). Notably, ET-1 and ETA-receptor gene expressions in the lymph
nodeswere signiﬁcantly upregulated after the 1st and 2ndMyHC-α im-
munizations, but not in the hearts (Fig. 1). Thus, the ET-1–ETA signal
may play a key role in the immune responses in the lymph nodes.
EAM is a CD4+ T cell-mediated disease (Eriksson et al., 2003;
Fairweather et al., 2001). The initial activation of naive antigen-speciﬁc
CD4+T cells occurs in the lymph nodes (Itano and Jenkins, 2003). There-
fore, we hypothesized that ET-1 had an effect on the CD4+ T-cell activa-
tion in the lymph nodes. To test this hypothesis, we stimulated CD4+ T
cells with ET-1 upon TCR stimulation but, unexpectedly, we did not
ﬁnd any direct effect of ET-1 on the CD4+ T-cell differentiation (Fig. 8).
Naïve antigen-speciﬁc CD4+ T cells are activated by the presentation
of peptide-major histocompatibility complex class II (MHC class II) com-
plexes on the APCs in the lymph nodes (Itano and Jenkins, 2003). From
these ﬁndings, ET-1 in the lymph nodes may inﬂuence the APCs, such as
DCs that are essential for priming and expanding the CD4+ T cells
(Eriksson et al., 2003), and consequently affect the CD4+ T-cell activa-
tion. In the present study, we found that ET–ETA receptor signaling up-
regulated the SOCS3 gene expression in DCs (Fig. 5B). Similar effects of
ET-1 on adipocytes have been reported (Chang et al., 2012). The authors
showed that the ET-1 stimulated SOCS3 gene expression in adipocytes
through the ETA-receptor, mitogen-activated protein kinase, Janus ki-
nase and phosphoinositide 3-kinase pathways, independent of the
ETB-receptor pathway. It has been reported that SOCS3-deﬁcient DCs
are aberrantly activated and promote Th1/Th17 cell differentiation, indi-
cating that SOCS3 serves to dampen the DC activation and subsequent
CD4+ T-cell differentiation (Qin et al., 2012). From these ﬁndings, the in-
hibition of the SOCS3 induction in DCs by ETA-receptor antagonists may
have promoted the T-cell differentiation,whichmayhave resulted in the
adverse effects of the SB209680 in EAM. Further studies are needed to
evaluate the role of the ET-1 in both innate and adaptive immunities.
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Th1-, Th2-, Th17- or Treg polarizing conditions for 48 h. (A) Th1 (IFN-γ), Th2 (IL-4) and Th17 (IL-17A) cytokine mRNA expression in CD4+ T cells was quantiﬁed by QRT-PCR. (B) The
percentage of Foxp3+ cells was analyzed by ﬂow cytometry. (C) ET-1 (10 nM) did not inﬂuence the T-cell differentiation in the absence or presence of selective ETA- or ETB-receptor an-
tagonist. Data are expressed as the mean ± SEM from triplicate wells. The results of one of two representative experiments are shown.
295K. Tajiri et al. / Life Sciences 118 (2014) 288–296The activation and differentiation of T cells play a critical role in the
pathogenesis of autoimmune myocarditis (Bergelson et al., 1997). To
the best of our knowledge there have been no reports on the effect of
ET on T-cell cytokine secretion. Our study examined the effect of an ET
receptor blockade on the Th response in EAM. In the present study,
in vivo treatment with an ET receptor blocker enhanced the Th17 cyto-
kine IL-17 production from cardiac-speciﬁc CD4+ T cells (Fig. 6) and re-
duced the number of inﬁltrating Tregs (Fig. 7), which was associated
with the disease severity. Th17 cells have been implicated in the patho-
genesis of various types of autoimmune diseases (Ghoreschi et al.,
2011). Tregs maintain immune homeostasis, prevent autoimmune
responses, and control themagnitude and duration of inﬂammatory re-
sponses (Lehtimaki and Lahesmaa, 2013). Caution must be exercised
during treatment of autoimmunemyocarditis when we use ET receptor
blockers, because they may increase the severity of the disease through
enhancing Th17 response and reducing the Tregs.
SOCS proteins were originally identiﬁed as negative-feedback regu-
lators in cytokine signaling (Dimitriou et al., 2008; Yoshimura et al.,
2007). The SOCS family is composed of eight members: cytokine-
inducible SRC homology 2 (SH2) domain-containing protein (CIS) and
SOCS1 to SOCS7 (Croker et al., 2008; Shuai and Liu, 2003). SOCS3 is a
key negative-feedback regulator of gp130, which is a common receptor
component of the IL-6 cytokine family (Yajima et al., 2011). It has been
reported that cardiac-speciﬁc SOCS3 knockout mice developed cardiacdysfunction and ventricular arrhythmias through the unregulated acti-
vation of gp130 signaling (Yajima et al., 2011). Although the underline
mechanism was unclear, SB209670 treatment downregulated the
SOCS3 gene expression in the heart (Fig. 5A). ET may have a protective
role in the preventing cardiac dysfunction and arrhythmias through the
SOCS3 induction.
There are a few publications on the effects of ET receptor blockers on
virus-inducedmyocarditismodels, but to the best of our knowledge, not
on EAM. In an encephalomyocarditis virus (EMCV)-inducedmyocarditis
model, treatment with Bosentan, an ETA/ETB dual receptor blocker, has
been shown to reduce cardiac hypertrophy (Seta et al., 2000), cellular
inﬁltration and myocardial necrosis, but it does not change the virus ti-
ters (Ono et al., 1999). Marchant et al. showed that Bosentan improved
the echocardiographic data, but enhanced the viral load andmyocarditis
severity in CVB3-inducedmyocarditis (Marchant et al., 2009). Thus, an-
tagonism of ET signaling is potentially a desirable therapeutic strategy
for cardiac hypertrophy; however it is still unclearwhether an ET recep-
tor blockade is useful for controlling the virus-induced myocarditis. In
the present study, we evaluated the effect of an ET receptor blockade
on myocarditis under infectious pathogen-free conditions, and treat-
ment with an ET receptor blocker exacerbated the disease severity.
From these ﬁndings, we must be careful when using ET receptor
blockers in patients in a state of both virus-induced myocarditis and
post-infectious myocarditis.
296 K. Tajiri et al. / Life Sciences 118 (2014) 288–296Conclusion
In conclusion, ET receptor antagonists exacerbated the autoimmune
myocarditis in mice. We provide a warning about the use of the ET re-
ceptor antagonists during myocarditis.
Conﬂict of interest statement
The authors declare that they have no conﬂict of interest.
Acknowledgments
We are grateful to Mr. John Martin for revising this manuscript.
References
BartonM, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA re-
ceptor blockade restores NO-mediated endothelial function and inhibits atheroscle-
rosis in apolipoprotein E-deﬁcient mice. Proc Natl Acad Sci U S A 1998;95:14367–72.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Iso-
lation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Sci-
ence 1997;275:1320–3.
Chang HH, Huang YM, Wu CP, Tang YC, Liu CW, Huang CH, et al. Endothelin-1 stimulates
suppressor of cytokine signaling-3 gene expression in adipocytes. Gen Comp
Endocrinol 2012;178:450–8.
Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway.
Semin Cell Dev Biol 2008;19:414–22.
Dimitriou ID, Clemenza L, Scotter AJ, Chen G, Guerra FM, Rottapel R. Putting out the ﬁre:
coordinated suppression of the innate and adaptive immune systems by SOCS1 and
SOCS3 proteins. Immunol Rev 2008;224:265–83.
Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, et al. Dendritic
cell-induced autoimmune heart failure requires cooperation between adaptive and
innate immunity. Nat Med 2003;9:1484–90.
Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. From infection to autoimmuni-
ty. J Autoimmun 2001;16:175–86.
Ghoreschi K, Laurence A, Yang XP, Hirahara K, O'Shea JJ. T helper 17 cell heterogeneity
and pathogenicity in autoimmune disease. Trends Immunol 2011;32:395–401.
Gretz JE, Anderson AO, Shaw S. Cords, channels, corridors and conduits: critical architec-
tural elements facilitating cell interactions in the lymph node cortex. Immunol Rev
1997;156:11–24.
Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat
Immunol 2003;4:733–9.
Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocar-
ditis. J Am Coll Cardiol 2012;59:779–92.
Lazzerini PE, Capecchi PL, Laghi-Pasini F. Statins as a new therapeutic perspective inmyo-
carditis and postmyocarditis dilated cardiomyopathy: editorial to “pitavastatin regu-
lates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice”
by K. Tajiri et al. Cardiovasc Drugs Ther 2013;27:365–9.
Lehtimaki S, Lahesmaa R. Regulatory T cells control immune responses through their
non-redundant tissue speciﬁc features. Front Immunol 2013;4:294.
Leuschner F, Katus HA, Kaya Z. Autoimmune myocarditis: past, present and future. J
Autoimmun 2009;33:282–9.Li Y, Chu N, Rostami A, Zhang GX. Dendritic cells transduced with SOCS-3 exhibit a
tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and
in vivo. J Immunol 2006;177:1679–88.
Maki S, Miyauchi T, Kakinuma Y, Sakai S, Kobayashi T, Sugiyama F, et al. The
endothelin receptor antagonist ameliorates the hypertensive phenotypes of
transgenic hypertensive mice with renin–angiotensin genes and discloses roles
of organ speciﬁc activation of endothelin system in transgenic mice. Life Sci
2004;74:1105–18.
Marchant D, Dou Y, Luo H, Garmaroudi FS, McDonough JE, Si X, et al. Bosentan enhances
viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein
kinase activation while improving cardiac function during Coxsackievirus-induced
myocarditis. Circ Res 2009;104:813–21.
Murakoshi N, Miyauchi T, Kakinuma Y, Ohuchi T, Goto K, Yanagisawa M, et al. Vascular
endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular re-
modeling after injury revealed by endothelin-B receptor-knockout mice. Circulation
2002;106:1991–8.
Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Contribution of endothelin-1 to
myocardial injury in a murine model of myocarditis: acute effects of bosentan, an
endothelin receptor antagonist. Circulation 1999;100:1823–9.
Qin H, YehWI, De Sarno P, Holdbrooks AT, Liu Y, Muldowney MT, et al. Signal transducer
and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3)
axis in myeloid cells regulates neuroinﬂammation. Proc Natl Acad Sci U S A
2012;109:5004–9.
Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocar-
dial endothelin pathway improves long-term survival in heart failure. Nature
1996;384:353–5.
Seta Y, Kanda T, Yokoyama T, Arai M, Sekiguchi K, Tanaka T, et al. Therapy with the
nonpeptide endothelin receptor antagonist 97–139 in a murine model of congestive
heart failure: reduction of cardiac mass and myoﬁber hypertrophy. Jpn Heart J
2000;41:79–85.
Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, Thornton AM. The lifestyle
of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev
2006;212:60–73.
Shuai K, Liu B. Regulation of JAK–STAT signalling in the immune system. Nat Rev Immunol
2003;3:900–11.
Sonderegger I, Iezzi G, Maier R, Schmitz N, Kurrer M, Kopf M. GM-CSF mediates autoim-
munity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med
2008;205:2281–94.
Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early
hours of acute myocardial infarction. J Am Coll Cardiol 1991;18:38–43.
Tajiri K, Imanaka-Yoshida K, Matsubara A, Tsujimura Y, Hiroe M, Naka T, et al. Suppressor
of cytokine signaling 1 DNA administration inhibits inﬂammatory and pathogenic re-
sponses in autoimmune myocarditis. J Immunol 2012;189:2043–53.
Tajiri K, Shimojo N, Sakai S, Machino-Ohtsuka T, Imanaka-Yoshida K, Hiroe M, et al.
Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune
myocarditis in mice. Cardiovasc Drugs Ther 2013;27:413–24.
Valaperti A, Marty RR, Kania G, Germano D, Mauermann N, Dirnhofer S, et al. CD11b+
monocytes abrogate Th17 CD4+ T cell-mediated experimental autoimmune myo-
carditis. J Immunol 2008;180:2686–95.
Yajima T, Murofushi Y, Zhou H, Park S, Housman J, Zhong ZH, et al. Absence of SOCS3 in
the cardiomyocyte increases mortality in a gp130-dependent manner accompanied
by contractile dysfunction and ventricular arrhythmias. Circulation 2011;124:
2690–701.
Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation.
Nat Rev Immunol 2007;7:454–65.
Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol
2007;8:457–62.
